Aditya Patel

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors

Anjaneya Chimalakonda, James R. Burke, Lihong Cheng et al. · Dermatology and Therapy · 2021 · 125 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Interim Results of a Phase 1/2 <scp>Open‐Label</scp> Study of <scp>INO</scp>‐3107 for <scp>HPV</scp>‐6 and/or <scp>HPV</scp>‐11‐Associated Recurrent Respiratory Papillomatosis

Ted Mau, Milan R. Amin, Peter C. Belafsky et al. · The Laryngoscope · 2023 · 35 citations · Full text

Life Sciences, Immunology, Oncology +16

DOP42 Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC study

Silvio Danese, Remo Panaccione, Geert D’Haens et al. · Journal of Crohn s and Colitis · 2022 · 21 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

965: EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: 12-WEEK RESULTS FROM THE PHASE 2 LATTICE-UC STUDY

Silvio Danese, Remo Panaccione, Geert D’Haens et al. · Gastroenterology · 2022 · 13 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis

Geert D’Haens, Silvio Danese, Remo Panaccione et al. · Journal of Crohn s and Colitis · 2025 · 11 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17